Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Total Current Liabilities: 2015-2025

Historic Total Current Liabilities for Assembly Biosciences (ASMB) over the last 11 years, with Sep 2025 value amounting to $53.4 million.

  • Assembly Biosciences' Total Current Liabilities rose 28.21% to $53.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.4 million, marking a year-over-year increase of 28.21%. This contributed to the annual value of $47.8 million for FY2024, which is 21.87% up from last year.
  • According to the latest figures from Q3 2025, Assembly Biosciences' Total Current Liabilities is $53.4 million, which was up 12.88% from $47.3 million recorded in Q2 2025.
  • In the past 5 years, Assembly Biosciences' Total Current Liabilities ranged from a high of $53.4 million in Q3 2025 and a low of $7.1 million during Q3 2023.
  • Its 3-year average for Total Current Liabilities is $34.7 million, with a median of $41.3 million in 2024.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first slumped by 53.87% in 2023, then skyrocketed by 483.78% in 2024.
  • Assembly Biosciences' Total Current Liabilities (Quarterly) stood at $16.1 million in 2021, then grew by 1.39% to $16.3 million in 2022, then spiked by 140.70% to $39.2 million in 2023, then rose by 21.87% to $47.8 million in 2024, then increased by 28.21% to $53.4 million in 2025.
  • Its last three reported values are $53.4 million in Q3 2025, $47.3 million for Q2 2025, and $46.6 million during Q1 2025.